Diagnostics and treatment of polymyalgia rheumatica

被引:5
作者
Dejaco, C. [1 ]
Matteson, E. L. [2 ,3 ,4 ,5 ]
Buttgereit, F. [6 ]
机构
[1] Med Univ Graz, Klin Abt Rheumatol, Graz, Austria
[2] Mayo Clin, Div Rheumatol, Dept Internal Med, Coll Med, Rochester, MN USA
[3] Mayo Clin, Div Epidemiol, Dept Internal Med, Coll Med, Rochester, MN USA
[4] Mayo Clin, Div Rheumatol, Dept Hlth Sci Res, Coll Med, Rochester, MN USA
[5] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Coll Med, Rochester, MN USA
[6] Charite, Med Klin Schwerpunkt Rheumatol & Klin Immunol, Charitepl 1, D-10117 Berlin, Germany
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2016年 / 75卷 / 07期
关键词
Epidemiology; Treatment; Monitoring; Arthritis; Autoimmune diseases; GIANT-CELL ARTERITIS; PROVISIONAL CLASSIFICATION CRITERIA; TERM-FOLLOW-UP; RHEUMATISM/AMERICAN COLLEGE; EUROPEAN LEAGUE; DOUBLE-BLIND; GLUCOCORTICOID THERAPY; 2015; RECOMMENDATIONS; ONSET; METHOTREXATE;
D O I
10.1007/s00393-016-0105-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymyalgia rheumatica (PMR) is the most common autoimmune inflammatory disease in older persons with an average age of onset of 73 years. Typical symptoms include acute or subacute bilateral shoulder pain with severe stiffness and often neck and bilateral hip pain. Giant cell arteritis (GCA) occurs in approximately 20 % of cases and up to two thirds of patients with GCA have symptoms of PMR. There are many disease which mimic PMR, elderly onset rheumatoid arthritis is frequently misdiagnosed as PMR. Although there are no specific laboratory tests, CaEuroreactive protein and erythrocyte sedimentation rates are elevated in over 90 % of patients. The diagnosis may be aided by imaging, especially ultrasonography and magnetic resonance imaging (MRI). Treatment currently consists of glucocorticoids at an initial dose of 12.5-25 mg prednisone equivalent daily. Treatment duration is typically 2aEuro3 years but may be longer. Under certain conditions low-dose methotrexate can be used as adjuvant therapy.
引用
收藏
页码:687 / 700
页数:14
相关论文
共 64 条
  • [1] Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series
    Adizie, T.
    Christidis, D.
    Dharmapaliah, C.
    Borg, F.
    Dasgupta, B.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (09) : 906 - 909
  • [2] Effective Control of Polymyalgia Rheumatica With Tocilizumab
    Al Rashidi, Abdulrahman
    Hegazi, Mohamed Osama
    Mohammad, Shaimaa A.
    Varghese, Alex
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2013, 19 (07) : 400 - 401
  • [3] Circulating cytokines in active polymyalgia rheumatica
    Alvarez-Rodriguez, L.
    Lopez-Hoyos, M.
    Mata, C.
    Jose Marin, M.
    Calvo-Alen, J.
    Blanco, R.
    Aurrecoechea, E.
    Ruiz-Soto, M.
    Martinez-Taboada, V. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) : 263 - 269
  • [4] EVALUATION OF CRITERIA FOR POLYMYALGIA RHEUMATICA
    BIRD, HA
    ESSELINCKX, W
    DIXON, ASJ
    MOWAT, AG
    WOOD, PHN
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1979, 38 (05) : 434 - 439
  • [5] Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients
    Blockmans, D.
    De Ceuninck, L.
    Vanderschueren, S.
    Knockaert, D.
    Mortelmans, L.
    Bobbaers, H.
    [J]. RHEUMATOLOGY, 2007, 46 (04) : 672 - 677
  • [6] Peripheral arterial disease in polymyalgia rheumatica
    Borg, Frances A.
    Dasgupta, Bhaskar
    [J]. ARTHRITIS RESEARCH & THERAPY, 2009, 11 (03)
  • [7] Cantini F, 2001, ARTHRITIS RHEUM, V44, P1155, DOI 10.1002/1529-0131(200105)44:5<1155::AID-ANR198>3.3.CO
  • [8] 2-E
  • [9] Cantini F, 2001, J RHEUMATOL, V28, P1049
  • [10] Prednisone plus methotrexate for polymyalgia rheumatica - A randomized, double-blind, placebo-controlled trial
    Caporali, R
    Cimmino, MA
    Ferraccioli, G
    Gerli, R
    Klersy, C
    Salvarani, C
    Montecucco, C
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 141 (07) : 493 - 500